The everything virus: Epstein-Barr's disease ledger is now big enough to price a vaccine

Epstein-Barr virus is carried by about 95 percent of people and in most of them never causes disease ^[1]. Science News reports that scientists now attribute both infectious mononucleosis and multiple sclerosis to that same virus ^[2], which moves a near-universal childhood infection out of the category of background fact and into the category of exposure someone could act on.

The burden is countable. EBV causes roughly 2 percent of cancers globally, amounting to nearly 360,000 new cases and up to 210,000 deaths a year ^[4]. That works out to about 0.58 deaths per new case ^[19], and it implies a global cancer denominator in the region of 18 million cases annually ^[21]. Add the autoimmune column, where MS sits alongside reported links to lupus and Sjogren's syndrome ^[3], and the shape of the problem is clear: because the exposure is almost everywhere, modest relative risks land on very large absolute totals. Roughly one person in twenty escapes infection ^[20]. Everyone else is a candidate.

Mechanism is the part that has moved. According to Stanford rheumatologist William Robinson, "EBV has developed to evade and escape the immune system at every juncture, because that's how it survives" ^[7]. Research has shown that the virus infects key immune cells and rewires the immune system to its own advantage ^[8], and there is evidence it mimics some human proteins, prompting immune attacks on healthy cells that express them ^[9]. MS is a disease in which the immune system attacks the myelin sheaths around neurons, producing symptoms from numbness and fatigue to difficulty walking and vision loss ^[11]. There is also growing evidence that EBV reactivates in some long COVID patients and contributes to their symptoms ^[10].

The timing is the hard part for anyone designing a prevention programme. Rae Mainwaring was diagnosed with mono at 13, missed six months of school in Birmingham, England, and attended part time for another six ^[12]. She was diagnosed with MS at 24 ^[13], eleven years after the mono ^[14]. Mono is most commonly diagnosed in teenagers and young adults and spreads through saliva ^[18], so the plausible intervention window sits a decade or more ahead of the endpoint that would matter most. Cancer endpoints are further out still.

Against that, the intervention shelf is empty. There are no antivirals and no approved vaccines for EBV, though some companies are testing candidates ^[5], and the virus is hard to clear because it tricks the immune system at every stage ^[6]. The virus was found in 1964, when Michael Anthony Epstein, Bert Achong and Yvonne Barr spotted viral particles in cells from Ugandan children with Burkitt's lymphoma ^[15], which is about 61 years of knowing what it is with nothing licensed against it ^[16]. That gap is not only a treatment gap. It is an evidence gap, because the cleanest test of a causal claim is to remove the exposure and count what fails to happen, and right now nobody can remove the exposure.

What to watch: whether any of the candidate vaccines reaches an efficacy trial with a stated endpoint, and which endpoint is chosen, since mono is measurable in years and MS is not; and whether mechanism work separates molecular mimicry from reactivation, which point to different drugs. Catherine Godbold of the MS Society in the UK says understanding how EBV works "could offer real hope for future treatment and prevention," and that momentum in EBV research is building ^[17]. That is the correct amount of confidence to have for now.